Opportunity overview
NHS Midlands & Lancashire Commissioning Support Unit (MLCSU) are acting on behalf of the Commissioner, NHS Staffordshire and Stoke-on-Trent Integrated Care Board (SSOT ICB). The ICB followed the Direct Award B process in accordance with the Health Care Services (Provider Selection Regime) (PSR) 2023 for the Provision of Consultant Led, Elective Care Services - Rheumatology, Gastroenterology, Endocrinology, with CPV Code 85112200-9 (Outpatient care services).
Awarded to
Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.
MEDEFER LIMITED
Matched by number
- Contract value
- £748k
- Awarded
- Not supplied
- Contract signed
- 30 Jun 2025
- Award ID
- 046685-2025-CMT-1362-1
- Status
- active
- Identifier
- GB-COH 08770754
- Location
- London, UK, W2 6LG, United Kingdom
Classification
- CPV85112200 — Outpatient care services
Lots
- Contract Award Notice for Direct Award B Process for the Provision of Consultant Led, Elective Care Services - Rheumatology, Gastroenterology, Endocrinology for Staffordshire and Stoke - on - Trent Integrated Care Board (ICB) NHS Midlands & Lancashire Commissioning Support Unit (MLCSU) are acting on behalf of the Commissioner, NHS Staffordshire and Stoke-on-Trent Integrated Care Board (SSOT ICB). The ICB followed the Direct Award B process in accordance with the Health Care Services (Provider Selection Regime) (PSR) 2023 for the Provision of Consultant Led, Elective Care Services - Rheumatology, Gastroenterology, Endocrinology with CPV Code 85112200-9 (Outpatient Services). The Direct Award B process involves awarding a contract to provider(s) where the services offered by the Provider are deemed Patient Choice, and the number of providers is not restricted by the relevant authority. The Provider has undergone the ICB Accreditation Process and passed all requirements. The contract is dated 01 July 2025 to 31 March 2027. The estimated lifetime value of the contract is £748,021 based on the ICB approved Indicative Activity Plan but excluding Endocrinology which will be determined in year. These are new services with an existing provider.Value not stated